Difference between revisions of "Binimetinib (Mektovi)"
Jump to navigation
Jump to search
(Created page with "=Mechanism of action= From the [http://www.cancer.gov/publications/dictionaries/cancer-drug?cdrid=653635 NCI Drug Dictionary]: An orally available inhibitor of mitogen-activat...") |
m |
||
| Line 1: | Line 1: | ||
=Mechanism of action= | =Mechanism of action= | ||
From the [http://www.cancer.gov/publications/dictionaries/cancer-drug?cdrid=653635 NCI Drug Dictionary]: An orally available inhibitor of mitogen-activated protein kinase kinase 1 and 2 (MEK1/2) with potential antineoplastic activity. Binimetinib, noncompetitive with ATP, binds to and inhibits the activity of MEK1/2. | From the [http://www.cancer.gov/publications/dictionaries/cancer-drug?cdrid=653635 NCI Drug Dictionary]: An orally available inhibitor of mitogen-activated protein kinase kinase 1 and 2 (MEK1/2) with potential antineoplastic activity. Binimetinib, noncompetitive with ATP, binds to and inhibits the activity of MEK1/2. | ||
| + | |||
| + | =Preliminary data= | ||
| + | |||
| + | ==[[Melanoma]]== | ||
| + | # Ascierto PA, Schadendorf D, Berking C, Agarwala SS, van Herpen CM, Queirolo P, Blank CU, Hauschild A, Beck JT, St-Pierre A, Niazi F, Wandel S, Peters M, Zubel A, Dummer R. MEK162 for patients with advanced melanoma harbouring NRAS or Val600 BRAF mutations: a non-randomised, open-label phase 2 study. Lancet Oncol. 2013 Mar;14(3):249-56. Epub 2013 Feb 13. [http://www.sciencedirect.com/science/article/pii/S147020451370024X link to SD article] [http://www.ncbi.nlm.nih.gov/pubmed/23414587 PubMed] | ||
=Also known as= | =Also known as= | ||
| Line 12: | Line 17: | ||
[[Category:Kinase inhibitors]] | [[Category:Kinase inhibitors]] | ||
[[Category:MEK inhibitors]] | [[Category:MEK inhibitors]] | ||
| + | |||
| + | [[Category:Melanoma medications]] | ||
[[Category:Investigational]] | [[Category:Investigational]] | ||
Revision as of 19:47, 24 August 2016
Mechanism of action
From the NCI Drug Dictionary: An orally available inhibitor of mitogen-activated protein kinase kinase 1 and 2 (MEK1/2) with potential antineoplastic activity. Binimetinib, noncompetitive with ATP, binds to and inhibits the activity of MEK1/2.
Preliminary data
Melanoma
- Ascierto PA, Schadendorf D, Berking C, Agarwala SS, van Herpen CM, Queirolo P, Blank CU, Hauschild A, Beck JT, St-Pierre A, Niazi F, Wandel S, Peters M, Zubel A, Dummer R. MEK162 for patients with advanced melanoma harbouring NRAS or Val600 BRAF mutations: a non-randomised, open-label phase 2 study. Lancet Oncol. 2013 Mar;14(3):249-56. Epub 2013 Feb 13. link to SD article PubMed
Also known as
ARRY-162, ARRY-438162